Type 1 diabetes reversed in mice 8 December 2014 Scientists researching type 1 diabetes have had a major breakthrough after successfully reversing the condition in mice. They hope their research could one day lead to reversing the condition in people. The University of Cincinnati scientists found that using an antibody called UT18 to stimulate a molecule called TLR4 prevented T-cells from attacking beta cells. This approach reversed type 1 diabetes in a large percentage of non-obese mice that had just developed the disease. The findings were recently presented at the American Diabetes Association meeting in San Francisco. While the research is yet to be peer-reviewed and is preliminary, it is exciting news for people with type 1 diabetes. Study leader Dr William Ridgway said the key to reversing type 1 diabetes in mice was to catch the disease when it first developed. He noted that the window of opportunity for treatment would be longer in humans, but would still be relatively brief. While animal research findings don’t often translate in human trials this approach is different from other attempts to combat type 1 diabetes in that it doesn’t directly target T-cells, according to Dr Ridgway. He said the therapy holds promise because one drug has already been approved by the U.S. Food and Drug Administration and others are under development.
Media releases 24 February 2026 Diabetes sector stands together in call for affordable access to technology The diabetes sector across Australia has come together to call for better access to life-changing diabetes technologies. Ahead of the... Continue Reading
News 23 February 2026 Diabetes Australia data secure Diabetes Australia has been contacted regarding a data breach at a diabetes organisation located in Victoria. The breach did not involve Diabetes Australia and we have been advised by... Continue Reading
Media releases 20 February 2026 Diabetes Australia appoints first Chief Health Officer Diabetes Australia has appointed Brett Fenton as its first Chief Health Officer marking a major step in strengthening clinical leadership and improving outcomes for people living with diabetes. Continue Reading